Download PDF
Arzneimittelforschung 2012; 62(12): 666-669
DOI: 10.1055/s-0032-1329986
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

A Validated HPLC Method for the Determination of Eriocalyxin B in Plasma and its Application to Pharmacokinetic Studies

Z. Wang
1   Department of General Surgery, Renji Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, China
,
Q. Yuan
2   Department Of Clinical Pharmacology, Shanghai Drugs Research And Development Center, Shanghai, China
,
J-h. Sun
1   Department of General Surgery, Renji Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, China
,
Z. Cui
1   Department of General Surgery, Renji Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, China
,
H-y. Chen
2   Department Of Clinical Pharmacology, Shanghai Drugs Research And Development Center, Shanghai, China
,
H. Wu
1   Department of General Surgery, Renji Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, China
,
J-x. Chen
1   Department of General Surgery, Renji Hospital, Shanghai Jiao tong University School of Medicine, Shanghai, China
› Author Affiliations
Further Information

Publication History

received 05 September 2012

accepted 25 October 2012

Publication Date:
15 November 2012 (online)

    Permissions and Reprints

Abstract

Background:

The purpose of this study was to determine EriB in plasma by using the method of HPLC and collect the preclinical pharmacokinetic parameters of EriB.

Method:

The analysis involved a simple liquid-liquid extraction. After making alkaline with NaOH, plasma was extracted with diethyl ether and the organic extract was then evaporated. From there, the residue was reconstituted in to the mobile phase. Chromatographic separation was achieved on the C18 column using acetonitrile and 0.1% triethylamine as mobile phase delivered at 1.0 ml/min. The UV detector wavelength was set at 233 nm. Standard curves were linear over the concentration range of 50–2 500 ng/ml.

Results:

The mean predicted concentrations of the quality control (QC) samples deviated by less than 3% from the corresponding nominal values; the intra-assay and inter-assay precision of the assay were within 10% relative standard deviation. The extraction recovery of EriB was more than 80%.

Conclusion:

The developed method has been applied to the pharmacokinetic study of EriB in rats.

Key words

biopharmaceuticals - gastrointestinal ­pharmacology - pharmacokinetic
 

  • References

  • 1 Ikezoe T, Chen SS, Tong XJ et al. Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 2003; 23: 1187-1193
    PubMedGoogle Scholar
  • 2 Leung CH, Grill SP, Lam W et al. Eriocalyxin B inhibits nuclear factor-kappaB activation by interfering with the binding of both p65 and p50 to the response element in a noncompetitive manner. Proc Am Assoc Cancer Res 2006; 70: 1946-1955
    PubMedGoogle Scholar
  • 3 Wang L, Zhao WL, Yan JS et al. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ 2007; 14: 306-317
    CrossrefPubMedGoogle Scholar
  • 4 Sun HD, Lin ZW, Niu FD. Diterpenoids from Isodon eriocalyx var. Laxiflora. Phytochemistry 1995; 38: 1451-1455
    CrossrefPubMedGoogle Scholar
  • 5 Leizer AL, Alvero AB, Fu HH et al. Regulation of inflammation by the NF-κB pathway in ovarian cancer stem cells. Am J Reprod Immunol 2011; 65: 438-447
    CrossrefPubMedGoogle Scholar
  • 6 Yang Y, Sun H, Zhou Y et al. Effects of three diterpenoids on tumour cell proliferation and telomerase activity. Nat Prod Res 2009; 23: 1007-1012
    CrossrefPubMedGoogle Scholar
  • 7 Sun HD, Xu YL, Jiang B. Diterpenoids from Isodon Species. Beijing: Science Press; 2001. 95-104
    Google Scholar